# 16-week Flexible vs. 8-week Semaglutide Titration

> **NCT04447859** · PHASE3 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes type2

## Interventions

- **DRUG:** Semaglutide
- **OTHER:** label recommended titration

## Key facts

- **NCT ID:** NCT04447859
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-23
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-09-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447859, "16-week Flexible vs. 8-week Semaglutide Titration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04447859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*